S 64315

Drug Profile

S 64315

Alternative Names: MIK 665; S64315

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier; Vernalis
  • Developer Novartis; Servier; Vernalis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 12 Jul 2017 Phase-I clinical trials in Lymphoma (Second-line therapy or greater) in Spain, Japan (IV) (NCT02992483)
  • 12 Jul 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in Spain, Japan (IV) (NCT02992483)
  • 15 Mar 2017 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Australia (IV) (NCT02979366)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top